The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | First-in-human trial of ALLO-501A in R/R large B-cell lymphoma
Allogeneic CAR T-cell therapy has the potential to address a number of shortcomings inherent in autologous CAR-T therapy in order to maximize potential CAR-T recipients and optimize patient outcomes. Michael Tees, MD, MPH, Colorado Blood Cancer Institute, Denver, CO, discusses the first-in-human data of ALLO-501A, an allogeneic CAR-T product under investigation in relapsed/refractory (R/R) large B-cell lymphoma in the ALPHA2 study (NCT04416984). ALLO-501A is engineered to reduce the risk of graft versus host disease and permit the use of an anti-CD42 monoclonal antibody (ALLO-647) for lymphodepletion. 11 patients were enrolled in the dose escalation cohort and preliminary data suggest an acceptable safety profile following ALLO-501A and ALLO-647 and early signs of efficacy in large B-cell lymphoma. Enrollment is ongoing. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
